The role of cilostazol in the treatment of intermittent claudication

A. H. Barnett, A. W. Bradbury, Julie Brittenden, B. Crichton, R. Donelly, S. Homer-Vanniasinkam, D. P. Mikhalidis, G. Stansby

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

This paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays n its treatment. IC is a common and debilitating condition that has a significant adverse impact on health-related quality of life (HR-QoL). It is currently under-recognised as a powerful marker of increased cardiovascular (CV) risk. The clinical priority is secondary prevention - sometimes referred to as best medical therapy aimed at reducing CV risk. However, the priority for most patients (often overlooked by clinicians) is symptom relief: an increase in walking distance leading to an improvement in HR-QoL. The symptoms of IC may be improved by exercise, pharmacotherapy, and when these are unsuitable or unsuccessful, endovascular or surgical intervention.

Cilostazol is indicated for the improvement of maximal and pain-free walking distance in patients with IC who do not have rest pain or tissue necrosis. In clinical trials, cilostazol improved symptoms both objectively and subjectively, and also improved HR-QoL. Cilostazol is usually well tolerated, with adverse events being generally mild to moderate in intensity, and transient or resolved after symptomatic treatment (e.g. non-prescription analgesics). Such events only infrequently require permanent drug withdrawal. There are no interactions with other drugs commonly prescribed in patients with IC, such as statins and anti-platelet agents. Cilostazol also has a range of potentially beneficial effects that may in the future be proven to decrease CV risk and modify the underlying process of atherosclerosis. Cilostazol represents the best evidence-based pharmacological therapy available for the symptoms of IC and should be the first-line treatment for symptom improvement in appropriate patients. Based on the available treatment strategies, the paper presents a suggested algorithm for the management of IC highlighting the role of cilostazol.

Original languageEnglish
Pages (from-to)1661-1670
Number of pages9
JournalCurrent Medical Research and Opinion
Volume20
Issue number10
DOIs
Publication statusPublished - 2004

Keywords

  • arterial occlusive diseases
  • atherosclerosis
  • cilostazol
  • intermittent claudication
  • peripheral arterial disease
  • PERIPHERAL ARTERIAL-DISEASE
  • CORONARY-HEART-DISEASE
  • SCANDINAVIAN SIMVASTATIN SURVIVAL
  • BLOOD-PRESSURE CONTROL
  • RANDOMIZED-TRIAL
  • MICROVASCULAR COMPLICATIONS
  • THERAPEUTIC ANGIOGENESIS
  • CARDIOVASCULAR-DISEASE
  • MYOCARDIAL-INFARCTION
  • ANTIPLATELET THERAPY

Cite this

Barnett, A. H., Bradbury, A. W., Brittenden, J., Crichton, B., Donelly, R., Homer-Vanniasinkam, S., ... Stansby, G. (2004). The role of cilostazol in the treatment of intermittent claudication. Current Medical Research and Opinion, 20(10), 1661-1670. https://doi.org/10.1185/030079904X4464

The role of cilostazol in the treatment of intermittent claudication. / Barnett, A. H.; Bradbury, A. W.; Brittenden, Julie; Crichton, B.; Donelly, R.; Homer-Vanniasinkam, S.; Mikhalidis, D. P.; Stansby, G.

In: Current Medical Research and Opinion, Vol. 20, No. 10, 2004, p. 1661-1670.

Research output: Contribution to journalArticle

Barnett, AH, Bradbury, AW, Brittenden, J, Crichton, B, Donelly, R, Homer-Vanniasinkam, S, Mikhalidis, DP & Stansby, G 2004, 'The role of cilostazol in the treatment of intermittent claudication', Current Medical Research and Opinion, vol. 20, no. 10, pp. 1661-1670. https://doi.org/10.1185/030079904X4464
Barnett, A. H. ; Bradbury, A. W. ; Brittenden, Julie ; Crichton, B. ; Donelly, R. ; Homer-Vanniasinkam, S. ; Mikhalidis, D. P. ; Stansby, G. / The role of cilostazol in the treatment of intermittent claudication. In: Current Medical Research and Opinion. 2004 ; Vol. 20, No. 10. pp. 1661-1670.
@article{ebf8f8107f064bdca5d3c4722ddd1b96,
title = "The role of cilostazol in the treatment of intermittent claudication",
abstract = "This paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays n its treatment. IC is a common and debilitating condition that has a significant adverse impact on health-related quality of life (HR-QoL). It is currently under-recognised as a powerful marker of increased cardiovascular (CV) risk. The clinical priority is secondary prevention - sometimes referred to as best medical therapy aimed at reducing CV risk. However, the priority for most patients (often overlooked by clinicians) is symptom relief: an increase in walking distance leading to an improvement in HR-QoL. The symptoms of IC may be improved by exercise, pharmacotherapy, and when these are unsuitable or unsuccessful, endovascular or surgical intervention.Cilostazol is indicated for the improvement of maximal and pain-free walking distance in patients with IC who do not have rest pain or tissue necrosis. In clinical trials, cilostazol improved symptoms both objectively and subjectively, and also improved HR-QoL. Cilostazol is usually well tolerated, with adverse events being generally mild to moderate in intensity, and transient or resolved after symptomatic treatment (e.g. non-prescription analgesics). Such events only infrequently require permanent drug withdrawal. There are no interactions with other drugs commonly prescribed in patients with IC, such as statins and anti-platelet agents. Cilostazol also has a range of potentially beneficial effects that may in the future be proven to decrease CV risk and modify the underlying process of atherosclerosis. Cilostazol represents the best evidence-based pharmacological therapy available for the symptoms of IC and should be the first-line treatment for symptom improvement in appropriate patients. Based on the available treatment strategies, the paper presents a suggested algorithm for the management of IC highlighting the role of cilostazol.",
keywords = "arterial occlusive diseases, atherosclerosis, cilostazol, intermittent claudication, peripheral arterial disease, PERIPHERAL ARTERIAL-DISEASE, CORONARY-HEART-DISEASE, SCANDINAVIAN SIMVASTATIN SURVIVAL, BLOOD-PRESSURE CONTROL, RANDOMIZED-TRIAL, MICROVASCULAR COMPLICATIONS, THERAPEUTIC ANGIOGENESIS, CARDIOVASCULAR-DISEASE, MYOCARDIAL-INFARCTION, ANTIPLATELET THERAPY",
author = "Barnett, {A. H.} and Bradbury, {A. W.} and Julie Brittenden and B. Crichton and R. Donelly and S. Homer-Vanniasinkam and Mikhalidis, {D. P.} and G. Stansby",
year = "2004",
doi = "10.1185/030079904X4464",
language = "English",
volume = "20",
pages = "1661--1670",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - The role of cilostazol in the treatment of intermittent claudication

AU - Barnett, A. H.

AU - Bradbury, A. W.

AU - Brittenden, Julie

AU - Crichton, B.

AU - Donelly, R.

AU - Homer-Vanniasinkam, S.

AU - Mikhalidis, D. P.

AU - Stansby, G.

PY - 2004

Y1 - 2004

N2 - This paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays n its treatment. IC is a common and debilitating condition that has a significant adverse impact on health-related quality of life (HR-QoL). It is currently under-recognised as a powerful marker of increased cardiovascular (CV) risk. The clinical priority is secondary prevention - sometimes referred to as best medical therapy aimed at reducing CV risk. However, the priority for most patients (often overlooked by clinicians) is symptom relief: an increase in walking distance leading to an improvement in HR-QoL. The symptoms of IC may be improved by exercise, pharmacotherapy, and when these are unsuitable or unsuccessful, endovascular or surgical intervention.Cilostazol is indicated for the improvement of maximal and pain-free walking distance in patients with IC who do not have rest pain or tissue necrosis. In clinical trials, cilostazol improved symptoms both objectively and subjectively, and also improved HR-QoL. Cilostazol is usually well tolerated, with adverse events being generally mild to moderate in intensity, and transient or resolved after symptomatic treatment (e.g. non-prescription analgesics). Such events only infrequently require permanent drug withdrawal. There are no interactions with other drugs commonly prescribed in patients with IC, such as statins and anti-platelet agents. Cilostazol also has a range of potentially beneficial effects that may in the future be proven to decrease CV risk and modify the underlying process of atherosclerosis. Cilostazol represents the best evidence-based pharmacological therapy available for the symptoms of IC and should be the first-line treatment for symptom improvement in appropriate patients. Based on the available treatment strategies, the paper presents a suggested algorithm for the management of IC highlighting the role of cilostazol.

AB - This paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays n its treatment. IC is a common and debilitating condition that has a significant adverse impact on health-related quality of life (HR-QoL). It is currently under-recognised as a powerful marker of increased cardiovascular (CV) risk. The clinical priority is secondary prevention - sometimes referred to as best medical therapy aimed at reducing CV risk. However, the priority for most patients (often overlooked by clinicians) is symptom relief: an increase in walking distance leading to an improvement in HR-QoL. The symptoms of IC may be improved by exercise, pharmacotherapy, and when these are unsuitable or unsuccessful, endovascular or surgical intervention.Cilostazol is indicated for the improvement of maximal and pain-free walking distance in patients with IC who do not have rest pain or tissue necrosis. In clinical trials, cilostazol improved symptoms both objectively and subjectively, and also improved HR-QoL. Cilostazol is usually well tolerated, with adverse events being generally mild to moderate in intensity, and transient or resolved after symptomatic treatment (e.g. non-prescription analgesics). Such events only infrequently require permanent drug withdrawal. There are no interactions with other drugs commonly prescribed in patients with IC, such as statins and anti-platelet agents. Cilostazol also has a range of potentially beneficial effects that may in the future be proven to decrease CV risk and modify the underlying process of atherosclerosis. Cilostazol represents the best evidence-based pharmacological therapy available for the symptoms of IC and should be the first-line treatment for symptom improvement in appropriate patients. Based on the available treatment strategies, the paper presents a suggested algorithm for the management of IC highlighting the role of cilostazol.

KW - arterial occlusive diseases

KW - atherosclerosis

KW - cilostazol

KW - intermittent claudication

KW - peripheral arterial disease

KW - PERIPHERAL ARTERIAL-DISEASE

KW - CORONARY-HEART-DISEASE

KW - SCANDINAVIAN SIMVASTATIN SURVIVAL

KW - BLOOD-PRESSURE CONTROL

KW - RANDOMIZED-TRIAL

KW - MICROVASCULAR COMPLICATIONS

KW - THERAPEUTIC ANGIOGENESIS

KW - CARDIOVASCULAR-DISEASE

KW - MYOCARDIAL-INFARCTION

KW - ANTIPLATELET THERAPY

U2 - 10.1185/030079904X4464

DO - 10.1185/030079904X4464

M3 - Article

VL - 20

SP - 1661

EP - 1670

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 10

ER -